Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. - Wikidata - awgldk - TriplyDB

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

http://www.wikidata.org/entity/Q52009327

about

A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma.Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma Enhanced cellular immunity in macaques following a novel peptide immunotherapy.Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.Vaccination immunotherapy--an update.Antigenic targets for renal cell carcinoma immunotherapy.A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.Dendritic cell vaccine strategies for renal cell carcinoma.Active and passive immunotherapy: vaccines and antibodies.Recent developments in renal cell cancer immunotherapy.Dendritic cell vaccination.Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook.CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential.Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease.Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials.Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma.Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells.Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells.Immunotherapy for renal cell carcinoma

P2860

Q24814644-0BAEB938-03C1-42E9-A148-BDAA8E0361BB Q27016032-CCD1CA41-F8C9-448C-8B85-6390F0E84F8F Q33724878-AC13221A-18B1-4AB7-9EE8-0DB0D8223C4B Q33726199-2D29E60D-6EA1-44A8-89E5-01C0E254DB50 Q33737787-3CDDA70B-52DD-4AFB-BA8A-481B99D21FEC Q33886261-CF681CC5-8EAE-4ED5-BDAB-CD1AA71208CA Q35851700-92F91857-AAFE-48FE-B47B-B03026DA6C3C Q35925619-8D6E91D7-C051-472F-B06D-5D29C2A11536 Q36696911-14D5CB68-5E0D-4474-ACA8-9650C0AEEA59 Q36717351-F781F7A6-37B5-4DC5-9854-D47F3FF6D6D2 Q36794818-3E1A3A5D-23DB-4138-AA77-DE1385C804D7 Q36810304-17555964-6271-4C79-BEEE-16CA788E6463 Q36899104-E74E73A2-1673-4536-B494-877E35EE2E5D Q37316009-F60FCC7D-0E68-4D9C-9A8D-76F04E737107 Q37336918-5F345C05-E135-4D2E-9C72-A6B6C3F72866 Q37514725-9400322D-FA24-4961-A61D-78205B15C7AD Q37892594-97E650ED-1C16-412B-B5C2-62B721785C42 Q38059516-33FEC3E3-E844-4528-9094-E8EFAB1F9670 Q38091116-4606E010-A1E5-4E51-AF64-7C914AE7D295 Q40416524-1EA8CC82-1860-4426-83C1-8D63245F1BF6 Q41205250-C635961C-B06F-4BB1-AC2D-2521D85CC3E9 Q47151222-04B78083-516A-4CFF-B61D-67EC6CC42613 Q58652034-C5A52C5A-EAB8-4811-A1DC-4064B68FC2C5

P2860

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

http://www.wikidata.org/entity/Q52009327

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Vaccination of patients with m ...... nterleukin-2: a phase 1 study.

@en

Vaccination of patients with m ...... nterleukin-2: a phase 1 study.

@nl

type

label

Vaccination of patients with m ...... nterleukin-2: a phase 1 study.

@en

Vaccination of patients with m ...... nterleukin-2: a phase 1 study.

@nl

prefLabel

Vaccination of patients with m ...... nterleukin-2: a phase 1 study.

@en

Vaccination of patients with m ...... nterleukin-2: a phase 1 study.

@nl

P1433

Q52009327-E7473604-7275-49E9-AD2C-59B2155D93B7

P1476

Q52009327-A59C5B41-7DC8-4697-B798-3A72D755BFF5

P2093

Q52009327-348C9982-3054-4C5E-89A1-8884E10300D0

Q52009327-49D84524-5F5A-4EC6-82E8-2360B1A5A963

Q52009327-50EE4287-5694-464D-B420-B4648E2C1675

Q52009327-8729554A-DC12-4B09-8F2B-697A168BD336

Q52009327-923FE2F9-C536-4747-97D2-B459DD6123C9

Q52009327-96B3C291-9DA4-4A2A-B8CE-318D3045BE31

Q52009327-A13932C6-A533-4335-8229-E9C656F698AB

Q52009327-A23F08D9-4AE3-4336-B2FC-38E2A0B170B3

Q52009327-E02939E4-F82B-4A7E-9EB7-21717EB50585

Q52009327-E1DE8910-5D9D-4F5F-BB74-17028DAC33B8

P304

Q52009327-09AB0216-3DA3-4C14-8683-C2F09CA9FF96

P31

Q52009327-C2B84A81-AD47-460A-8083-20DC7AEBC67C

P356

Q52009327-A2D96600-971A-45AA-A4AE-D1E3F73FE52C

P433

Q52009327-A4D0588F-27AF-4B36-B5BD-D4D7C97EAE4C

P478

Q52009327-9F5C2BFA-36C5-4C08-885C-47C52FE0F521

P577

Q52009327-C0FF2A60-7B55-4021-A672-E93F694CD6B1

P698

Q52009327-CF3E2220-BC98-4002-933F-917A2B865307

P356

00002371-200211000-00006

P1433

Journal of Immunotherapy

P1476

Vaccination of patients with m ...... nterleukin-2: a phase 1 study.

@en

P2093

Dorien M Tiemessen

http://www.w3.org/2001/XMLSchema#string

Egbert Oosterwijk

http://www.w3.org/2001/XMLSchema#string

Frans M J Debruyne

http://www.w3.org/2001/XMLSchema#string

Gosse J Adema

http://www.w3.org/2001/XMLSchema#string

I Jolanda M de Vries

http://www.w3.org/2001/XMLSchema#string

Ivar Bleumer

http://www.w3.org/2001/XMLSchema#string

Jeannette C Oosterwijk-Wakka

http://www.w3.org/2001/XMLSchema#string

Peter F A Mulders

http://www.w3.org/2001/XMLSchema#string

Pieter H de Mulder

http://www.w3.org/2001/XMLSchema#string

Wim Jongmans

http://www.w3.org/2001/XMLSchema#string

P304

500-508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00002371-200211000-00006

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12439347

http://www.w3.org/2001/XMLSchema#string